Cardiovascular Division, Department of Medicine, Center for Interdisciplinary Cardiovascular Sciences (E.A., M.C.B.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Cardiovascular Division, Department of Medicine, Center for Excellence in Vascular Biology (E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):117-127. doi: 10.1161/ATVBAHA.120.314704. Epub 2020 Oct 29.
Cardiovascular calcification is an insidious form of ectopic tissue mineralization that presents as a frequent comorbidity of atherosclerosis, aortic valve stenosis, diabetes, renal failure, and chronic inflammation. Calcification of the vasculature and heart valves contributes to mortality in these diseases. An inability to clinically image or detect early microcalcification coupled with an utter lack of pharmaceutical therapies capable of inhibiting or regressing entrenched and detectable macrocalcification has led to a prominent and deadly gap in care for a growing portion of our rapidly aging population. Recognition of this mounting concern has arisen over the past decade and led to a series of revolutionary works that has begun to pull back the curtain on the pathogenesis, mechanistic basis, and causative drivers of cardiovascular calcification. Central to this progress is the discovery that calcifying extracellular vesicles act as active precursors of cardiovascular microcalcification in diverse vascular beds. More recently, the omics revolution has resulted in the collection and quantification of vast amounts of molecular-level data. As the field has become poised to leverage these resources for drug discovery, new means of deriving relevant biological insights from these rich and complex datasets have come into focus through the careful application of systems biology and network medicine approaches. As we look onward toward the next decade, we envision a growing need to standardize approaches to study this complex and multifaceted clinical problem and expect that a push to translate mechanistic findings into therapeutics will begin to finally provide relief for those impacted by this disease.
心血管钙化是异位组织矿化的一种隐匿形式,常作为动脉粥样硬化、主动脉瓣狭窄、糖尿病、肾衰竭和慢性炎症的合并症出现。血管和心脏瓣膜的钙化会导致这些疾病的死亡率升高。临床上无法对微钙化进行成像或检测,再加上缺乏能够抑制或逆转已形成且可检测的大钙化的药物疗法,这导致在我们快速老龄化的人口中,越来越多的人在治疗方面存在显著且致命的空白。过去十年中,人们已经认识到这一日益严重的问题,并开展了一系列革命性的工作,开始揭示心血管钙化的发病机制、机制基础和致病驱动因素。这方面的核心进展是发现钙化细胞外囊泡(calcifying extracellular vesicles)是各种血管床心血管微钙化的活跃前体。最近,组学革命导致了大量分子水平数据的收集和量化。随着该领域准备利用这些资源进行药物发现,通过仔细应用系统生物学和网络医学方法,从这些丰富而复杂的数据集得出相关生物学见解的新方法成为焦点。展望未来十年,我们预计对研究这一复杂且多方面临床问题的方法进行标准化的需求将会增加,并期望将机制研究结果转化为治疗方法的努力将开始为受这种疾病影响的人提供缓解。